ADA/EASD position statement of the treatment of type 2 diabetes: Reply to Rodbard HW and Jellinger PS [letter], Scheen AJ [letter] and Ceriello A, Gallo M, Gentile S et al [letter]

Diabetologia

Volumn 55, Issue 10, 2012, Pages 2856-2857

  Matthews, D R ^a,b,c   Inzucchi, S E ^d  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b Oxford Biomedical Research Centre ^*  (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ADA; EASD; Guideline; Position statement; Treatment; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLICLAZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA; VILDAGLIPTIN;

ALGORITHM; BLOOD GLUCOSE MONITORING; CLINICAL DECISION MAKING; DRUG COST; GLUCOSE BLOOD LEVEL; GOVERNMENT; HUMAN; LETTER; MEDICAL SOCIETY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL;

ALGORITHMS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; INDIVIDUALIZED MEDICINE; METFORMIN; SOCIETIES, MEDICAL;

EID: 84866065910     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2669-z     Document Type: Letter

References (7)

1. Rodbard HW, Jellinger PS (2012) A critique of the 2012 ADA/EASD position statement. Diabetologia doi: 10.1007/s00125-012-2646-6
2. Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577-1596
3. Scheen AJ (2012) Controversy about the relative efficacy of dipeptidyl peptidase IV inhibitors. Diabetologia doi: 10.1007/s00125-012-2635-9
4. Foley JE, Sreenan S (2009) Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm Metab Res 41:905-909
5. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A (2012) Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 344:e1369
6. Ceriello A, Gallo M, Gentile S, Giorda CB, De Micheli A, on behalf of Associazione Medici Diabetologi (AMD). Diabetologia doi: 10.1007/s00125-012- 2642-x
7. International Diabetes Federation (2011) 2011 Guideline for management of postmeal glucose in diabetes. IDF, Brussels. Available from http://www.idf.org/2011-guideline-management-postmeal-glucose-diabetes